151 related articles for article (PubMed ID: 35130368)
1. Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.
Zahra E; Chen R; Nielsen S; Tran AD; Santo T; Degenhardt L; Farrell M; Byrne J; Ali R; Larance B
Drug Alcohol Rev; 2022 May; 41(4):841-850. PubMed ID: 35130368
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions.
Tran AD; Chen R; Nielsen S; Zahra E; Degenhardt L; Santo T; Farrell M; Larance B
Int J Drug Policy; 2022 Jan; 99():103472. PubMed ID: 34649203
[TBL] [Abstract][Full Text] [Related]
3. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
4. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
5. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
[TBL] [Abstract][Full Text] [Related]
6. Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022.
Bharat C; Chidwick K; Gisev N; Farrell M; Ali R; Degenhardt L
Int J Drug Policy; 2024 Jan; 123():104255. PubMed ID: 38029481
[TBL] [Abstract][Full Text] [Related]
7. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
8. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
9. Administration and patient-incurred costs associated with opioid agonist treatment in Norway.
Pedersen MH; Danø A; Gibbons C; Jensen R
Curr Med Res Opin; 2022 Nov; 38(11):1959-1965. PubMed ID: 36172758
[TBL] [Abstract][Full Text] [Related]
10. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
[TBL] [Abstract][Full Text] [Related]
11. Global opioid agonist treatment: a review of clinical practices by country.
Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
[TBL] [Abstract][Full Text] [Related]
12. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
[TBL] [Abstract][Full Text] [Related]
13. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S
Drug Alcohol Rev; 2019 Sep; 38(6):690-698. PubMed ID: 31577058
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
16. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
17. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
19. Identifying the most common barriers to opioid agonist treatment in an Australian setting.
Hall NY; Le L; Abimanyi-Ochom J; Teesson M; Mihalopoulos C
Aust J Prim Health; 2023 Oct; 29(5):445-454. PubMed ID: 36934460
[TBL] [Abstract][Full Text] [Related]
20. Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.
Jones NR; Nielsen S; Farrell M; Ali R; Gill A; Larney S; Degenhardt L
Drug Alcohol Depend; 2021 Feb; 219():108464. PubMed ID: 33360851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
